Viking Therapeutics(VKTX)2025-02-05 21:07Financial Performance - For the three months ended December 31, 2024, Viking reported a net loss of 0.32 per share, compared to a net loss of 0.25 per share, in the same period in 2023[25]. - For the year ended December 31, 2024, Viking reported a net loss of 1.01 per share, compared to a net loss of 0.91 per share, in 2023[28]. - Viking's total operating expenses for the year ended December 31, 2024, were 100.8 million in 2023, reflecting a 49.7% increase[36]. - General and administrative expenses rose to 8.8 million in Q4 2023, driven by legal, patent services, and professional fees[24]. - General and administrative expenses for the year ended December 31, 2024, were 37.0 million in 2023[27]. - Research and development expenses increased to 20.5 million in Q4 2023, primarily due to manufacturing and personnel costs[23]. - For the year ended December 31, 2024, research and development expenses were 63.8 million in 2023[26]. - As of December 31, 2024, Viking held cash, cash equivalents, and short-term investments of 362 million as of December 31, 2023[29]. - The company's total assets as of December 31, 2024, were 368.5 million as of December 31, 2023[38]. Clinical Development - The Phase 2 VENTURE study of VK2735 for obesity achieved statistically significant mean body weight reductions of up to 14.7% from baseline and 13.1% relative to placebo[6]. - The company plans to initiate Phase 3 studies for VK2735 in obesity in Q2 2025[5]. - In the Phase 2b VOYAGE trial, VK2809 demonstrated a median relative reduction in liver fat content ranging from 38% to 55% after 12 weeks[13]. - VK2809-treated patients showed MASH resolution rates of 63% to 75% compared to 29% for placebo[14]. - The Phase 1b study of VK0214 in X-ALD resulted in a 38% reduction in plasma levels of a key biomarker relative to placebo[20]. - Viking is developing VK2735, a dual agonist for metabolic disorders, which has shown positive signs of clinical benefit in Phase 1 and Phase 2 trials[31]. - VK2809, a small molecule for lipid and metabolic disorders, achieved both primary and secondary endpoints in a Phase 2b study for NASH and fibrosis[32]. - The company is also developing VK0214 for the treatment of X-ALD, which demonstrated significant reductions in plasma levels of VLCFAs in a Phase 1b trial[32]. - Viking plans to file an IND application for its dual amylin and calcitonin receptor agonist program later this year[22]. - The company expects to report data from the VENTURE-Oral Dosing trial in 2H25, evaluating VK2735 as an oral tablet[12].